Literature DB >> 17255784

The role of HOX genes in malignant myeloid disease.

Elizabeth A Eklund1.   

Abstract

PURPOSE OF REVIEW: The Hox family of homeodomain transcription factors plays an important role in regulating definitive hematopoiesis. Recent studies indicate that a common characteristic of poor prognosis acute myeloid leukemia is dysregulated expression of a key group of these Hox proteins. The purpose of this review is to outline recent progress in understanding the role that dysregulation of HOX-gene expression plays in the pathogenesis of myeloid leukemogenesis. RECENT
FINDINGS: A number of recent studies correlate increased expression of HOXA-genes with poor prognosis cytogenetics in acute myeloid leukemia and mixed lineage leukemia. These studies determine that specific ABD HOXA-genes (HoxA7, 9 and 10) are dysregulated as a group. Many such studies also document co-overexpression of homeodomain proteins of the Meis and Pbx families in poor prognosis leukemia. This is of interest, since Meis and Pbx proteins are common DNA-binding partners for Hox proteins.
SUMMARY: These findings suggest that a key characteristic of poor prognosis acute myeloid leukemia is increased, differentiation-stage inappropriate expression of the Abd HoxA proteins and their DNA-binding partners. Such results suggest that dysregulation of the 'Hox code' is important in the pathogenesis of myeloid malignancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17255784     DOI: 10.1097/MOH.0b013e32801684b6

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  40 in total

1.  Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Sebastian Schwind; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Kelsi B Holland; Dean Margeson; Susan P Whitman; Christopher Hickey; Heiko Becker; Klaus H Metzeler; Peter Paschka; Claudia D Baldus; Shujun Liu; Ramiro Garzon; Bayard L Powell; Jonathan E Kolitz; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Guido Marcucci; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

2.  Geminin deletion from hematopoietic cells causes anemia and thrombocytosis in mice.

Authors:  Kathryn M Shinnick; Elizabeth A Eklund; Thomas J McGarry
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

3.  The histone variant macroH2A is an epigenetic regulator of key developmental genes.

Authors:  Marcus Buschbeck; Iris Uribesalgo; Indra Wibowo; Pau Rué; David Martin; Arantxa Gutierrez; Lluís Morey; Roderic Guigó; Hernán López-Schier; Luciano Di Croce
Journal:  Nat Struct Mol Biol       Date:  2009-09-06       Impact factor: 15.369

4.  Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors.

Authors:  Francesca Ficara; Laura Crisafulli; Chenwei Lin; Masayuki Iwasaki; Kevin S Smith; Luca Zammataro; Michael L Cleary
Journal:  J Cell Sci       Date:  2013-05-09       Impact factor: 5.285

5.  RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.

Authors:  Won-Il Kim; Ilze Matise; Miechaleen D Diers; David A Largaespada
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

6.  Targeting HOX and PBX transcription factors in ovarian cancer.

Authors:  Richard Morgan; Lynn Plowright; Kevin J Harrington; Agnieszka Michael; Hardev S Pandha
Journal:  BMC Cancer       Date:  2010-03-10       Impact factor: 4.430

7.  Integrative meta-analysis of differential gene expression in acute myeloid leukemia.

Authors:  Brady G Miller; John A Stamatoyannopoulos
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

8.  In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.

Authors:  Anmaar M Abdul-Nabi; Enas R Yassin; Nobish Varghese; Hrishikesh Deshmukh; Nabeel R Yaseen
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

9.  HOX proteins and leukemia.

Authors:  Kajal V Sitwala; Monisha N Dandekar; Jay L Hess
Journal:  Int J Clin Exp Pathol       Date:  2008-03-30

10.  HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer).

Authors:  L Plowright; K J Harrington; H S Pandha; R Morgan
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.